New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
14:31 EDTAMRNAmarin weakness unwarranted, says Leerink
Leerink believes that Amarin is weak today due to a negative Seeking Alpha article that provides no new information. The firm thinks it's too early to deem the company's Vascepa launch a commercial failure and sees FDA acceptance of the Vascepa sNDA in mixed dyslipidemia in late April/early May as an important catalyst. The firm maintains an Outperform rating.
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
16:50 EDTAMRNAmarin files $300M mixed securities shelf
16:12 EDTAMRNAmarin reports Q2 adjusted EPS (14c), consensus (15c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use